-
Something wrong with this record ?
Detection of the GPI-anchorless prion protein fragment PrP226* in human brain
E Dvorakova, T Vranac, O Janouskova, M Cernilec, S Koren, A Lukan, J Novakova, R Matej, K Holada, Serbec V Curin
Language English Country Great Britain
Grant support
NT14145
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
E-resources NLK Online Full text
BioMedCentral from 2001-12-01BioMedCentral Open Access from 2001
Directory of Open Access Journals from 2001
Free Medical Journals from 2001
PubMed Central from 2001
Europe PubMed Central from 2001
ProQuest Central from 2009-01-01
Open Access Digital Library from 2001-01-01
Open Access Digital Library from 2001-01-01
Open Access Digital Library from 2001-01-01
Medline Complete (EBSCOhost) from 2001-12-18
Health & Medicine (ProQuest) from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources from 2001
Springer Nature OA/Free Journals from 2001-12-01
Links
PubMed
24063733
DOI
10.1186/1471-2377-13-126
Knihovny.cz E-resources
- MeSH
- Creutzfeldt-Jakob Syndrome * pathology MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Endopeptidase K pharmacology MeSH
- Glycosylphosphatidylinositols metabolism MeSH
- Humans MeSH
- Brain * metabolism drug effects MeSH
- 14-3-3 Proteins metabolism MeSH
- PrPSc Proteins metabolism drug effects MeSH
- Statistics as Topic MeSH
- Temperature MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
BACKGROUND: The accumulation of the misfolded forms of cellular prion protein, i.e. prions (PrPSc), in the brain is one of the crucial characteristics of fatal neurodegenerative disorders, called transmissible spongiform encephalopathies (TSEs). Cellular prion protein is normally linked to the cell surface by the glycosylphosphatidylinositol (GPI) anchor. There is accumulating evidence that the GPI-anchorless prion protein may act as an accelerator of formation and propagation of prions. In the TSE affected human brain we have previously discovered a novel GPI-anchorless prion protein fragment, named PrP226*, which ends with the tyrosine 226. This fragment can be labeled specifically by the monoclonal antibody V5B2. METHODS: We developed a DELFIA based assay for quick and sensitive detection of the PrP226* fragment in human brain tissue homogenates. By calculating the ratio between the signals of native (N) and denatured (D) samples applied to the assay we were able to observe significant difference between 24 TSE affected brains and 10 control brains. The presence of PrP226* in brain tissue was confirmed by western blot. RESULTS: Our results demonstrate that PrP226* is present in small quantities in healthy human brain, whereas in degenerated brain it accumulates in prion aggregates, proportionally to PrPSc. Samples with high D/N ratio generally comprised more proteinase K resistant PrP, while no correlation was found between the quantity of PrP226* and standard classification of Creutzfeldt-Jakob disease (CJD). CONCLUSIONS: In the present study we show that the PrP226* fragment accumulates in prion aggregates and after being released from them by a denaturation procedure, could serve as a proteinase K digestion independent biomarker for human TSEs. The PrP226* assay described in this paper offers a tool to follow and study this unique anchorless PrP fragment in various parts of human brain and possibly also in other tissues and body fluids.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18034491
- 003
- CZ-PrNML
- 005
- 20190104103706.0
- 007
- ta
- 008
- 181009s2013 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/1471-2377-13-126 $2 doi
- 035 __
- $a (PubMed)24063733
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Dvořáková, Eva $7 _AN046206 $u Institute of Immunology and Microbiology, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic
- 245 10
- $a Detection of the GPI-anchorless prion protein fragment PrP226* in human brain / $c E Dvorakova, T Vranac, O Janouskova, M Cernilec, S Koren, A Lukan, J Novakova, R Matej, K Holada, Serbec V Curin
- 520 9_
- $a BACKGROUND: The accumulation of the misfolded forms of cellular prion protein, i.e. prions (PrPSc), in the brain is one of the crucial characteristics of fatal neurodegenerative disorders, called transmissible spongiform encephalopathies (TSEs). Cellular prion protein is normally linked to the cell surface by the glycosylphosphatidylinositol (GPI) anchor. There is accumulating evidence that the GPI-anchorless prion protein may act as an accelerator of formation and propagation of prions. In the TSE affected human brain we have previously discovered a novel GPI-anchorless prion protein fragment, named PrP226*, which ends with the tyrosine 226. This fragment can be labeled specifically by the monoclonal antibody V5B2. METHODS: We developed a DELFIA based assay for quick and sensitive detection of the PrP226* fragment in human brain tissue homogenates. By calculating the ratio between the signals of native (N) and denatured (D) samples applied to the assay we were able to observe significant difference between 24 TSE affected brains and 10 control brains. The presence of PrP226* in brain tissue was confirmed by western blot. RESULTS: Our results demonstrate that PrP226* is present in small quantities in healthy human brain, whereas in degenerated brain it accumulates in prion aggregates, proportionally to PrPSc. Samples with high D/N ratio generally comprised more proteinase K resistant PrP, while no correlation was found between the quantity of PrP226* and standard classification of Creutzfeldt-Jakob disease (CJD). CONCLUSIONS: In the present study we show that the PrP226* fragment accumulates in prion aggregates and after being released from them by a denaturation procedure, could serve as a proteinase K digestion independent biomarker for human TSEs. The PrP226* assay described in this paper offers a tool to follow and study this unique anchorless PrP fragment in various parts of human brain and possibly also in other tissues and body fluids.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a proteiny 14-3-3 $x metabolismus $7 D048948
- 650 12
- $a mozek $x metabolismus $x účinky léků $7 D001921
- 650 12
- $a Creutzfeldtova-Jakobova nemoc $x patologie $7 D007562
- 650 02
- $a endopeptidasa K $x farmakologie $7 D019286
- 650 02
- $a ELISA $7 D004797
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a glykosylfosfatidylinositoly $x metabolismus $7 D017261
- 650 02
- $a lidé $7 D006801
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a PrPSc proteiny $x metabolismus $x účinky léků $7 D018620
- 650 02
- $a statistika jako téma $7 D013223
- 650 02
- $a teplota $7 D013696
- 700 1_
- $a Vranac T
- 700 1_
- $a Janoušková, Olga $7 xx0100922 $u Institute of Immunology and Microbiology, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic; Institute of Macromolecular Chemistry v.i.i. Czech Republic
- 700 1_
- $a Cernilec M
- 700 1_
- $a Koren S
- 700 1_
- $a Lukan A
- 700 1_
- $a Nováková, Jana $u Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Matěj, Radoslav, $d 1974- $7 xx0103860 $u Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic
- 700 1_
- $a Holada, Karel $7 xx0061473 $u Institute of Immunology and Microbiology, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic
- 700 1_
- $a Curin Serbec V
- 773 0_
- $t BMC Neurology $g č. 13 (2013), s. 126 $p BMC Neurol $x 1471-2377 (elektronická verze) $w MED00008195
- 773 0_
- $p BMC Neurol $g 13:126, 2013 Sep 25
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20181009140615 $b ABA008
- 991 __
- $a 20190104103901 $b ABA008
- 999 __
- $a ok $b bmc $g 1340578 $s 1031488
- BAS __
- $a 3
- BMC __
- $a 2013 $c 13 $d 126 $x MED00008195 $i 1471-2377 (elektronická verze) $m BMC neurology
- GRA __
- $a NT14145 $p MZ0
- LZP __
- $a NLK 2018/lp